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ROLE OF NEUROPEPTIDE TYROSINE (NPY) IN ETHANOL ADDICTION  
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Valentina Carito2 
1Institute of Translational Pharmacology, CNR, Rome, Italy, 2Institute of Cell Biology and Neurobiology, 
CNR/IRCCS, S. Lucia Foundation, Rome, Italy, and 3Centro Riferimento Alcologico Regione Lazio, 
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Here, an overview of neurophysiological, pharmacological and genetic research on the role of neuropeptide tyrosine (NPY) 
in ethanol consumption and withdrawal is presented. NPY is abundantly expressed in the extended amygdala and is critically 
involved in the regulation of negative affective states in rats, also is involved with neurobiological responses to ethanol and other 
drug of abuse. Genetic, molecular and pharmacological evidences suggest that NPY is an important neurobiological substrate for 
the predisposition to alcoholism. Administration, as well as the withdrawal of ethanol, alters central NPY expression. Alcohol-
preferring rats exhibit basal NPY deficits in central amygdala. In the latter, NPY may rescue dependence-induced increases in 
anxiety and alcohol drinking. Low NPY levels in some brain regions following ethanol withdrawal contribute to the increased 
sensitivity to seizure and the heightened levels of anxiety characteristic of withdrawal responses. Mice with deletion of NPY gene 
exhibit a high-anxiety, high-alcohol-drinking phenotype. Pharmacological and genetic manipulations suggest that central NPY 
signaling modulates ethanol consumption via Y1, Y2, and Y5 receptors. Analysis of chromosomal regions (QTLs) associated 
with alcohol consumption identified NPY as one of the genes that influence alcohol dependence and as a promising target for 
pharmacotherapeutics to combat alcohol associated disorders. Consequently, NPY is a potentially new pharmacological target 
for the treatment of alcohol diseases. Biomed Rev 2016; 27: 27-39
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Abbreviations used
AA: Alko, Alcohol
BLA: basolateral amygdala 
BNST: bed nucleus of stria terminalis 
cAMP: cyclic AMP 
CeA: central nucleus of the amygdala 
CFR: corticotropin releasing factor 
eIPSCs: evoked inhibitory postsynaptic 
currents 
GABAARs: GABAA receptors 
GABAergic: γ-aminobutyricacidergic
HAD: high alcohol-drinking 
HEP: high-ethanol preferring 
HPA: hypothalamic-pituitary-adrenal 
LAD: low alcohol-drinking
MAPK: mitogen-activated protein 
kinase
NAc: nucleus accumbens 
NP: Alcohol-Nonpreferring 
NPY: neuropeptide tyrosine 
P: Alcohol-Preferring 
QTL: Quantitative Trait Locus
Y1Rs: post-synaptic NPY receptors 
Y2Rs: pre-synaptic NPY receptors    
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INTRODUCTION
Neuropeptide tyrosine (NPY) is a 36-amino acid neuropeptide, 
belonging to the PP-fold family of peptides (1) that results 
from cleavage of a 97-amino acid precursor, preproNPY. 
NPY exhibits a high degree of phylogenetic conservation 
across species (2,3) and is widely expressed in the central 
nervous system, particularly in the striatum, amygdala, cortex 
and hypothalamus (4,5). The neuropeptide functions through 
G protein-coupled receptors to suppress adenylyl cyclase, 
switch on mitogen-activated protein kinase (MAPK), trigger 
potassium channels and balance intracellular levels of calcium. 
At least five NPY receptor subtypes have been identified in 
mammals (6), of which the best characterized are Y1, Y2, and 
Y5 receptors (7).
In the brain NPY is produced in a lot of regions and controls 
several functions as neuronal development (8,9), food intake 
(10,11), seizure activity (12,13), cardiovascular homeostasis 
(14), anxiety and stress behaviors (15,16), thermogenesis 
(17), circadian rhythms (18,19), pain modulation (20), and 
reproduction (21,22). In recent years, genetic, pharmacological 
and molecular evidences have emerged suggesting that NPY is 
also associated with neurobiological responses to ethanol and 
drugs of abuse (23–25) and is important for the predisposition 
to alcohol-seeking behaviors (26).
NPY is abundant in the extended amygdala, a conceptual 
macrostructure in the basal forebrain holding the central nucleus 
of the amygdala (CeA), lateral division of the bed nucleus of 
stria terminalis (BNST), and shell of nucleus accumbens (NAc) 
(27). These regions of the extended amygdala display similar 
cytoarchitecture, overlapping afferents from limbic cortices, 
hippocampus, and basolateral amygdala (BLA). The outputs 
of the extended amygdala largely project to effector regions, 
including lateral hypothalamus and various brain stem regions 
important for physiological and behavioral responses to relevant 
emotive stimuli (e.g., stressors, alcohol, and drugs) (28,29).
The extended amygdala plays an important role in regulation 
of negative affective (e.g., anxiety) states (30). The constituent 
regions of the extended amygdala are densely populated by 
neuropeptides with pro-stress (e.g., corticotropin releasing factor, 
CFR) and anti-stress (e.g., NPY and nociceptin) profiles (7).
The CeA is composed mostly of γ-aminobutyricacidergic 
(GABAergic) projection neurons and interneurons (31), and 
the BNST is a major target of CeA projection neurons (32). 
CeA and BNST connections often contain neuropeptide co-
transmitters. For example, CeA is a major source of CRF in 
the BNST (33,34).
EFFECTS OF ETHANOL INTAKE ON NPY EXPRESSION
Long-Evans rats feeding a liquid diet that include 6% ethanol 
for 12 weeks show significant increases in NPY levels in the 
arcuate and ventromedial nuclei of the hypothalamus, the 
median eminence, and the suprachiasmatic nucleus when 
compared to rats that drank a control diet (35). Similarly, 
peripheral injection of 1.5 and 3.5 g/kg ethanol causes 
activation of NPY-containing neurons in the ventrolateral 
medulla of Long-Evans rats (36). It has been hypothesized 
that the increment of NPY activity in response to ethanol may 
serve as a mechanism of protection to limit further ethanol 
intake (37). However, ethanol administration and withdrawal 
from ethanol reduce NPY signaling mRNANPY levels in arcuate 
nucleus of the hypothalamus are reduced in Sprague-Dawley 
rats after a single peripheral injection of a 1.0 g ethanol/kg 
dose (38). Twenty-four hours after withdrawal from a diet 
containing 9% ethanol (after 15 days of exposure), Sprague-
Dawley rats show decreased NPY immunoreactivity in the 
cingulated gyrus, various regions of the cortex, the central and 
medial nuclei of the amygdala, and the paraventricular and 
arcuate nuclei of the hypothalamus (39). Wistar rats exposed to 
ethanol vapor for 14 h/day show no differences in brain NPY 
expression after 7 weeks of exposure, but do have increased 
NPY expression in the hypothalamus 7 weeks after withdrawal 
from ethanol (40). More recently, in Sprague-Dawley rats an 
increase of NPY immunoreactivity in the hippocampus 72-h 
after withdrawal from an ethanol diet was observed. The 
authors argue that increased NPY expression may be protective 
against seizure activity that develops after ethanol withdrawal 
(41). Thus, immediately after withdrawal from ethanol, NPY 
levels are low in some brain regions that control increased 
seizure activity and heightened levels of anxiety characteristic 
of ethanol withdrawal (23,42,43). This is followed by an 
upregulation of NPY in the hippocampus, a possible protective 
response. The evidences supporting this hypothesis comes 
from the finding that intracerebroventricular (i.c.v.) infusion 
of NPY significantly weakens ethanol withdrawal responses 
in Wistar rats (44). These data indicate that central NPY 
signaling regulates neurobiological responses to ethanol and 
ethanol withdrawal (26). 
THE IMPACT OF ALCOHOL ON GABAERGIC TRANSMISSION 
AND NPY
γ-Aminobutyric acid (GABA) is the major inhibitory 
neurotransmitter in the brain. It acts via two receptor subtypes 
called GABAA and GABAB. GABA activity in the brain is 
29
Biomed Rev 27, 2016
NPY in ethanol addiction
increased by alcohol through two general mechanisms: the 
action on the GABA-releasing presynaptic neurons, that 
increase GABA release; or the action on the signal-receiving 
postsynaptic neurons, that facilitate the activity of the GABAA 
receptors (GABAARs). Alcohol drinking is suppressed by 
compounds that interfere with the actions of the GABAARs 
antagonists as well as compounds that stimulate GABAB 
receptor agonists in the NAs, ventral pallidum, BNST, and 
amygdala (45). Of these, CeA, a brain region relevant in the 
control of emotional states, is highly responsive to suppression 
of alcohol drinking by compounds acting on the GABA systems 
(46). Indeed, GABA transmission in this brain region increases 
after acute and chronic alcohol exposure (47,48). GABAA 
receptors consist of several proteins subunits. There are several 
types of GABAA subunits, and the subunit composition of the 
receptors varies among different brain regions and remodels in 
response to environmental changes. Chronic alcohol exposure 
also leads to alterations in the GABA systems. For instance, 
in some brain regions, alcohol affects the expression of genes 
that encode components of the GABAA receptors, resulting in 
changes in the composition of the subunit of the receptors, the 
most consistent of which are decreases in α1-and increases in 
α4-subunits (49). The function of GABAA receptors also is 
regulated by neuroactive steroids (50) that are produced both 
in the brain and in other organs. Alcohol increases the brain 
levels of many neuroactive steroids (51).
Antagonists of GABAARs in CeA lower alcohol self-
administration in rats (46). Acute alcohol increases GABAergic 
synaptic transmission in CeA (47), and this effect is fast, 
reversible, and with a significant pre-synaptic component. 
Chronic alcohol exposure facilitates GABA release in the 
CeA, largely via actions at presynaptic GABAergic terminals 
(48,52). Acute alcohol enhances GABAergic transmission 
similarly in the CeA of alcohol-naïve and alcohol-dependent 
rats, suggesting that this brain region is particularly sensitive to 
the acute effects of alcohol (48). Because antagonists of GABA 
raceptors in BNST also reduce alcohol self-administration in 
rats (46), it is reasonable to hypothesize that the effects of 
alcohol on inhibitory transmission in BNST may be similar 
to effects in CeA.
NPY prevents and reverses acute alcohol-induced increases 
in evoked GABAergic transmission in CeA via pre-synaptic 
effects on GABA release (53). NPY blocks alcohol effects on 
GABA release via activation of pre-synaptic receptors (Y2Rs) 
in slice electrophysiology recordings from the CeA of rats. 
NPY alone does not decrease GABAergic transmission in CeA 
unless post-synaptic receptors (Y1Rs) are blocked, suggesting 
that functional Y1Rs in CeA ‘‘buffer’’ the effects of NPY at 
pre-synaptic Y2Rs. Notably, NPY normalizes GABA release in 
CeA, increased by alcohol dependence, suggesting that chronic 
alcohol produces neuroadaptations in NPY system that affect 
inhibitory transmission in CeA (53). In agreement with these 
findings, NPY lowers evoked inhibitory postsynaptic currents 
(eIPSCs) in the CeA of mice, and this effect intensifies in 
slices from mice with a history of binge alcohol drinking (54). 
Similar to its effects in CeA, NPY modulates GABA release in 
BNST (55) via activation of pre-synaptic Y2Rs, supporting the 
notion that Y2Rs  function not only as autoreceptors regulating 
NPY release (56) but also as heteroreceptors modulating the 
release of other neurotransmitters (57).
CORTICOTROPIN-RELEASING FACTOR AND NPY SYSTEMS
Recent research has led to the hypothesis that the transitions 
to alcohol dependence dysregulates not only neural circuits 
of reward but also circuits that are involved in behavioral 
responses to stressors. Perturbation of the brain stress 
and antistress systems induced by alcohol contributes 
to the negative emotional state characteristic of alcohol 
withdrawal. One stress system involves the signaling 
molecule CRF. The latter, being produced and released from 
hypothalamus, activates the body’s major stress system that 
is the hypothalamic-pituitary-adrenal (HPA) axis. However, 
activation of extrahypothalamic CRF systems also produces 
high anxiety states in animals. Several observations indicate 
that the development of alcohol dependence is triggered by 
extrahypothalamic CRF. For example, alcohol-dependent 
rats exhibit increased extracellular CRF content in CeA (58). 
Moreover, the injection of CRF antagonists directly into this 
brain structure suppress both the anxiety-like behavior (59) and 
the increase in alcohol drinking (60)  associated with alcohol 
dependence. NPY is also involved in regulating the body’s 
stress response. It has a neural and behavioral profile that in 
almost every aspect is opposite to that of CRF. NPY has potent 
anxiety-reducing effects in animals and alcohol-dependent rats 
exhibit decreased NPY content in CeA during withdrawal (39). 
In contrast, as stated above, CRF levels in this brain region 
are increased in alcohol-dependent animals. Furthermore, 
stimulation of NPY activity in this brain structure suppresses 
anxiety-like behavior (61) and increased in alcohol drinking 
induced by dependence (62). The anatomical distributions of 
CRF and NPY are highly overlapping, suggesting that one 
might serve as a “buffer” for the effects of the other. 
30
Biomed Rev 27, 2016
Ciafrè et al
NPY EFFECTS ON ALCOHOL DEPENDENCE-RELATED 
BEHAVIORS
Alcohol dependence is a disease characterized by a negative 
emotional state in absence of the drug (63, 64). The 
transition to alcohol dependence causes a dysregulation 
in neurotransmission in CeA mediated by neuropeptide 
systems (65). NPY is highly expressed in CeA and controls 
negative affective states in rats. Alcohol dependence produces 
neuroadaptation in amygdala NPY systems. This neuropeptide 
displays anxiolytic properties when infused into amygdala 
(16,66) and can rescue the high-anxiety associated with 
excessive drinking state in alcohol dependence. Studies on 
rats showed that NPY microinjected into the CeA blocks 
alcohol consumption in alcohol-dependent rats (67). This effect 
involves both postsynaptic Y1Rs and presynaptic Y2Rs. In 
the mouse, studies observed that acute stress and withdrawal 
increase Y1R expression in the amygdala.
Increases in alcohol self-administration during subsequent 
withdrawals (53), is a hallmark of the transition to alcohol 
dependence. This effect is blocked by repeated intraventricular 
NPY administration during prior alcohol withdrawals. It may 
be due to NPY reversal of anxiety-like behavior induced by 
withdrawal, as it has been observed with other anti-anxiety 
compounds chronically administered in a similar protocol (68). 
Activation of NPY systems in the CeA suppresses alcohol 
self-administration in alcohol-dependent rats at doses that do 
not affect alcohol self-administration in non-dependent rats 
(61,67). Chronic high-dose alcohol exposure and withdrawals 
in rats cause deficits in mRNA NPY and protein in CeA and a 
parallel increase in anxiety-like behavior (39,69). Finally, NPY 
reverts the alcohol-seeking behavior induced by stress (70, 71), 
probably through its effects on inhibitory neurotransmission 
in CeA (53). NPY effects on post dependent alcohol-related 
behaviors are likely mediated by presynaptic Y2Rs. Indeed 
intraventricular administration of a Y2R antagonist (BIIE0246) 
reduces alcohol consumption by rats (71) and mice (54), and 
during protracted abstinence, in alcohol-dependent rats, it 
was observed that the sensitivity to the suppressive effects 
of BIIE0246 on alcohol drinking increases (72). Systemic 
administration of an Y2R antagonist (JNJ-31020028), able to 
cross the blood-brain barrier, dose-dependently reverses the 
increased anxiety-like behavior in rats during withdrawal from 
a single bolus injection of alcohol (73). NPY systems in the 
extended amygdala may constitute a promising target in the 
search for potential pharmacotherapeutics to combat alcohol 
use disorders in humans (7).
HOW NPY SIGNALING MODULATES ETHANOL INTAKE: SOME 
HYPOTHESES
To understand the mechanism by which NPY signaling 
modulates ethanol consumption, some assumptions have 
been made. One possibility is that NPY influences ethanol 
consumption by regulating anxiety. While there are data 
that supports this hypothesis, there is evidence that NPY can 
modulate ethanol consumption independent of its effects on 
anxiety. Anxiety-like behavior (regardless of alcohol history) 
is affected by NPY release regulated by Y2R, whereas 
NPY modulation of alcohol-drinking behavior in alcohol-
dependent animals occurs via Y2R regulation of GABA 
release. Alcohol dependence produces changes in expression 
of NPY and its receptors, but the effects of NPY on excessive 
alcohol drinking by alcohol-dependent (and perhaps alcohol-
preferring) animals is mostly mediated by the recruitment of 
Y2R  heteroreceptor function and NPY-GABA interactions 
in the amygdala. Electrophysiological data have shown 
that Y2R antagonist (BIIE0246) applied to rat CeA slices 
increases evoked GABAergic transmission and blocks the 
ability of  NPY to abolish alcohol effects on GABA release 
(53). Therefore, Y2R antagonists mimic the effects of NPY 
in the CeA on anxiety-like behavior, but have the opposite 
result of the effects of NPY on alcohol consumption in 
alcohol-dependent animals and also in NPY effects on GABA 
release in CeA. Therefore, there would appear to be a delicate 
balance between the autoreceptor and heteroreceptor functions 
of pre-synapticY2Rs in CeA, a balance that may differ in 
non-dependent and alcohol-dependent states, and also across 
individuals. Another set of predictions that come out from 
the electrophysiological data is that infusion of a GABAAR 
antagonist into the CeA should reduce alcohol drinking and 
that pre-treatment with a GABAAR antagonist bypasses the 
effect of manipulation of pre-synaptic NPY and CRF receptors 
on alcohol drinking. The latter of these hypotheses has not 
been tested, but the infusion of a competitive GABAAR 
antagonist (SR 95531) into the amygdala, in particular, the 
CeA, does reduce alcohol self-administration in rats (46). 
Blocking GABAergic transmission with a drug peripherally 
administered is not viable as a long-term strategy for treating 
alcohol dependence in humans. As such, a more promising 
approach may be to target neuromodulators (e.g., NPY, CRF) 
of inhibitory transmission that is recruited (e.g., in the extended 
amygdala) during the transition to alcohol dependence.
Another possibility is that central NPY signaling controls 
the rewarding properties associated with ethanol. The NAc 
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is a brain structure in which the highest levels of NPY 
immunoreactivity has been observed (74). Also, the NAc is 
a crucial brain region for the modulation of ethanol reward 
(75). NPY infused directly into the NAc supports conditioned 
place preference in rats, indicating that NPY signaling in the 
NAc is rewarding (76,77). Furthermore, pretreatment with a 
dopamine receptor antagonist prevents NPY from producing 
conditioned place preference, suggesting that NPY-mediated 
reward involves an interaction with the dopamine system (77). 
A recent report found that the high ethanol drinking C57BL/6 
strain of mice has a significantly lower expression of NPY 
in the shell of the NAc relative to the low ethanol drinking 
DBA/2 strain (78). Thus, low NPY function in the NAc may, 
in part, drive the high ethanol drinking in C57BL/6 mice (26).
NPY KNOCKOUT AND TRANSGENIC RODENTS
Genetic manipulations demonstrated that central NPY 
signaling modulates neurobiological responses to ethanol and 
ethanol withdrawal. The phenotype of mice with deletion of the 
NPY gene is characterized by excessive alcohol consumption 
and reduced sensitivity to the sedative effects of high alcohol 
doses (37). Conversely, transgenic mice that overexpress NPY 
consume less alcohol than controls and display increased 
sensitivity to the sedative effects of high alcohol doses (37). 
Mice with deletion of the Y1R gene are very similar to NPY 
KO mice because they consume high quantities of alcohol 
and exhibit reduced sensitivity to the sedative effects of 
alcohol (79). Mice lacking the Y2R consume normal or lower 
quantities of alcohol relative to controls (80).
Pharmacological and/or genetic manipulations have 
implicated the Y1R, Y2R and Y5Rs in the modulation of 
ethanol intake. In the mouse, NPY acts through at least five 
receptor subtypes, namely Y1R, Y2R, Y4R, Y5R and Y6Rs, 
all of which couple to G proteins that inhibit the production 
of cyclic AMP (cAMP) (81). The Y1R is located post-
synaptically and is found in brain regions that are involved 
with neurobiological responses to ethanol, including the 
hippocampus, the hypothalamus and the amygdala (82). The 
Y2R is primarily located presynaptically where it acts as 
an autoreceptor, inhibiting further release of NPY (83,84). 
The Y5R is located post-synaptically, primarily in the 
hypothalamus, and has been hypothesized to be critically 
involved in the regulation of food intake (85). Voluntary 
ethanol intake by Y1R knockout mice (Y1R -/-) and by normal 
wild-type (Y1R +/+) mice was recently examined (79). 
Y1R-/-mice display increased consumption of solutions 
containing 3%, 6%, and 10% (v/v) ethanol but show normal 
consumption of sucrose and quinine solutions suggesting that 
increased consumption of ethanol is not associated with altered 
taste preference or caloric need. If presynaptic Y2 receptors 
control voluntary ethanol consumption and sensitivity, the 
Y2R-/- mice should exhibit ethanol-related phenotypes 
opposite to those found with the Y1R-/- mice. That is, in the 
absence of presynaptic inhibition of NPY release in Y2R-/- 
mice there should be an augment of NPY signaling. The Y2R-/- 
mice drink significantly less of solutions containing 3% and 6% 
ethanol and have significantly lower ethanol preference ratios 
relative to wild-type (Y2R+/+) mice, an effect that is genetic 
background-dependent. However, the Y2R-/- mice show 
normal consumption of solutions containing either sucrose or 
quinine and normal metabolism of ethanol. The observation 
that mRNAY2R is reduced in the high ethanol drinking AA 
(Alko, Alcohol) line of rats is additional evidence for a role 
of the Y2R in modulating alcohol drinking (86). Recent work 
indicates that mutant mice lacking Y5R (Y5R-/-) drink normal 
amounts of 3%, 6%, 10% and 20% (v/v) ethanol (87).
Together, data from NPY receptor knockout mice suggest 
that voluntary consumption of ethanol is modulated by Y1R 
and Y2R, but not the Y5R. Pharmacological data strengthen 
genetic studies and suggest a role for Y1R, Y2R and Y5R. 
First, direct infusion of femtomolar doses of NPY into the 
PVN of the hypothalamus increases consumption of ethanol 
by Long–Evans rats, and this effect is blocked by pretreatment 
with the Y1R selective antagonist, BIBP 3226 (88). Recently, 
it was shown that site-directed infusion of BIBP 3226 into 
the amygdala increases ethanol self-administration by 
Long–Evans rats (89). Second, i.c.v. infusion of the selective 
Y2 receptor antagonist, BIIE0246, reduces operant self-
administration of ethanol in Wistar rats at doses that do not 
interfere with normal locomotor activity (71). Finally, a recent 
report showed that i.p. injection of a selective Y5R antagonist 
does not alter absolute ethanol self-administration over a 16-h 
test but increases the latency to initiate operant responding 
for ethanol by C57BL/6J mice. Thus, also the NPY Y5R may 
regulate the onset of ethanol self-administration (90).
NPY IN ANIMAL MODELS OF ALCOHOL DEPENDENCE
Several animal models have been proposed to investigate 
alcohol related diseases (91–96) mechanisms and effects. 
Indeed, many studies aimed to unravel brain neurotransmitters’ 
changes, including NPY. Some of the best evidence that NPY 
plays a role in neurobiological responses to ethanol comes 
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from studies comparing the Indiana Alcohol-Preferring (P) 
and Alcohol-Nonpreferring (NP) rats. 
The P and NP lines were selectively bred from Wistar rats 
for high and low alcohol consumption, respectively (97). In this 
model, P rats exhibit several features that are consistent with 
alcoholism in humans (98). For instance, P rats (a) orally self-
administer ethanol in pharmacologically relevant amounts; (b) 
consume ethanol for its pharmacological effects (not caloric 
value or taste); (c) show positive reinforcement; (d) develop 
tolerance; and (e) exhibit withdrawal symptoms (99, 100). To 
date, a plethora of correlative studies has been conducted to 
study the behavioral and neurobiological differences between 
the P and NP lines (100). 
P and NP rats show opposite electrophysiological activity 
in the amygdala following  i.c.v.infusion of  NPY (101), 
suggesting that altered NPY signaling in the amygdala of P 
rats contributes to their high alcohol drinking. It was later 
discovered that P rats have low levels of NPY in the amygdala, 
frontal cortex, and hippocampus relative to NP rats, but higher 
levels of NPY in the hypothalamus and cingulate cortex 
(40,102). Similarly, the high alcohol-drinking (HAD) rats, 
bred by the technique used to generate the P rats, also have 
low levels of NPY in the amygdala when compared with low 
alcohol drinking (LAD) rats. Unlike the P rats, however, the 
HAD rats have lower levels of NPY in hypothalamic nuclei 
(102). Taken together the high alcohol drinking by the P and 
HAD rats are best explained by the low levels of endogenous 
NPY in the amygdala observed in each of these lines, i.c.v. 
infusion of 5.0 or 10.0 lg doses of NPY significantly reduce 2-h 
voluntary consumption of an 8% ethanol solution in P rats, but 
do not alter ethanol drinking in NP or outbred Wistar rats (103). 
Similarly, 5.0 or 10.0 lg doses of NPY reduce ethanol drinking 
in HAD, but not LAD, rats (104). P rats given i.c.v. infusion 
of a 10.0-lg dose of NPY show suppressed ethanol drinking 
for up to 2-days following a 2-week period of abstinence from 
ethanol. Without ethanol abstinence, a 10.0 lg dose of NPY 
reduces ethanol drinking for only 24-h. These data demonstrate 
that centrally infused NPY alters ethanol drinking by P rats for 
long periods of time, an effect that is potentiated by abstinence 
(105). The overall pattern of results from pharmacological 
studies suggests the possibility that central infusion of NPY 
can reduce ethanol drinking in animal models showing high 
levels of voluntary ethanol consumption (i.e., the P and HAD 
rats) but not in animals with low or moderate levels of ethanol 
consumption (i.e., NP, LAD, and Wistar rats). Genetic linkage 
analyses (e.g., quantitative trait locus) in P and NP rats have 
also suggested a role for NPY. 
A quantitative trait locus (QTL) is a section of DNA (the 
locus) that is associated with a particular phenotypic trait 
and correlates with variation in a phenotype (the quantitative 
trait). Usually, the QTL is linked to, or contains, the genes 
that control that phenotype. QTLs are mapped by identifying 
which molecular markers (such as SNPs or AFLPs) correlate 
with an observed trait. This is often an early step in identifying 
and sequencing the actual genes that cause the trait variation. 
Another use of QTLs is to identify candidate genes 
underlying a trait. Once a region of DNA is identified as 
contributing to a phenotype, it can be sequenced. The DNA 
sequence of any genes in this region can then be compared 
to a database of DNA for genes whose function is already 
known. Quantitative trait loci analyses identified a region of 
chromosome 4 that significantly correlates with differences in 
alcohol drinking between P and NP rats. The NPY precursor 
gene is located in this chromosomal region (106,107). It is 
interesting to note that a similar QTL located on chromosome 4 
has been correlated with the high ethanol drinking of the high-
ethanol preferring (HEP) line of rats (108). This QTL region 
defines a finite chromosomal interval with a limited number 
of genes. With current bioinformatics tools, all possible genes 
underlying a QTL region can now be identified. Combined 
with other bioinformatics resources, each of these genes can 
be screened for their potential relevance to the quantitative 
trait of interest, thus, providing targets for molecular-based 
research (109). Therefore, the literature and bioinformatics 
afford a complementary tool that can help demarcate a specific 
gene of interest from a broad QTL region with a multitude of 
differentially expressed genes (110). Ultimately, the genes for 
neuropeptide Y (Npy), Snca and corticotrophin-releasing factor 
receptor 2 (Crhr2) were prioritized for further characterization 
using molecular-based research because they: (a) exhibit a 
close proximity to the peak of the linkage signal; (b) show 
biological correlates that are relevant to alcohol dependence 
or an alcohol-related phenotype; and (c) display differences 
in gene expression (RNA, protein) between the P and NP 
strains. Molecular-based strategies can be effectively used 
to screen and target genes that contribute to a QTL. Three 
candidate genes (Npy, Snca, Crhr2) were initially screened and 
selected based on their proximity to the peak of the QTL and 
their gene expression profile. The identification of promising 
genetic targets (i.e. Npy, Snca, Crhr2) that map to a QTL and 
show strain-specific molecular and phenotypic correlations 
can provide a starting point for hypothesis-driven research that 
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better define the relevance of each candidate gene (Npy, Snca, 
Crhr2) to alcohol dependence. In humans, a polymorphism 
in Npy (Leu7Pro) was significantly associated with alcohol 
dependence in human alcoholics (111,112). It has been 
well-documented that the P and NP strains exhibit marked 
differences in anxiety-like behavior with studies suggesting 
that P rats are more “anxious” than NP rats. Compared with NP 
rats, P rats: (a) showed greater foot-shock-induced suppression 
of operant responding in an approach-avoidance conflict 
test; (b) spent less time in the open arms of an elevated plus 
maze; and (c) took longer in a passive avoidance test to step 
down from a platform to a grid floor where foot shock was 
received 24 hours earlier (113). In addition, both acoustic 
startle and potentiated startle response were consistently 
greater in P than NP rats, and only P rats showed significant 
fear-conditioned startle (114). Therefore, due to NPY’s role 
in the modulation of behavioral effects of stress, particularly 
anxiety-like behavior (115), Npy may represent an important 
biologic target for alcohol-seeking behavior, especially in the 
P and NP model. The identification of the genetic factors that 
influence addictive behavior can provide important targets for 
both basic and clinical research. In the P and NP model, QTL 
mapping (QTL analysis, fine-mapping) and molecular-based 
research were implemented as complementary approaches to 
identify and prioritize promising genetic targets for alcohol-
seeking behavior. With the recent advancements in molecular 
biology and bioinformatics, QTL mapping and molecular-
based strategies applied to selectively bred and inbred strains 
provide a multifaceted approach to target high-priority genes 
that contribute to alcohol dependence. NPY may represent 
an important biologic target for alcohol-seeking behavior, 
especially in the P and NP model. The identification of the 
genetic factors that influence addictive behavior can provide 
important targets for both basic and clinical research in the 
P and NP model. The overall objective of this research is to 
implement a multifaceted approach to target high-priority 
genes that contribute to alcohol dependence and are eligible 
for pharmaceutical development of new therapies.
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